ChemoCentryx, Inc. Forms 3, 4 and 5: Preferred Stock
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 38 rows, 38 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2012-02-13: Reporting owner ORBIMED ADVISORS LLC | ORBIMED CAPITAL LLC | OrbiMed Capital GP I LLC | ISALY SAMUEL D; Form 4; Security Series B Preferred Stock; Transaction C Conversion of derivative security.
- 2012-02-13: Reporting owner ORBIMED ADVISORS LLC | ORBIMED CAPITAL LLC | OrbiMed Capital GP I LLC | ISALY SAMUEL D; Form 4; Security Series C Preferred Stock; Transaction C Conversion of derivative security.
- 2012-02-13: Reporting owner ORBIMED ADVISORS LLC | ORBIMED CAPITAL LLC | OrbiMed Capital GP I LLC | ISALY SAMUEL D; Form 4; Security Series B Preferred Stock; Transaction C Conversion of derivative security.
- 2012-02-13: Reporting owner ORBIMED ADVISORS LLC | ORBIMED CAPITAL LLC | OrbiMed Capital GP I LLC | ISALY SAMUEL D; Form 4; Security Series C Preferred Stock; Transaction C Conversion of derivative security.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2012-02-13 | ORBIMED ADVISORS LLC | ORBIMED CAPITAL LLC | OrbiMed Capital GP I LLC | ISALY SAMUEL D 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series B Preferred Stock Derivative · Indirect · See Footnotes | C Conversion of derivative security | −78,928 0 owned after | no price filed | 2012-02-15 | |
| 2012-02-13 | ORBIMED ADVISORS LLC | ORBIMED CAPITAL LLC | OrbiMed Capital GP I LLC | ISALY SAMUEL D 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series C Preferred Stock Derivative · Indirect · See Footnotes | C Conversion of derivative security | −10,706 0 owned after | no price filed | 2012-02-15 | |
| 2012-02-13 | ORBIMED ADVISORS LLC | ORBIMED CAPITAL LLC | OrbiMed Capital GP I LLC | ISALY SAMUEL D 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series B Preferred Stock Derivative · Indirect · See Footnotes | C Conversion of derivative security | −3,888,423 0 owned after | no price filed | 2012-02-15 | |
| 2012-02-13 | ORBIMED ADVISORS LLC | ORBIMED CAPITAL LLC | OrbiMed Capital GP I LLC | ISALY SAMUEL D 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series C Preferred Stock Derivative · Indirect · See Footnotes | C Conversion of derivative security | −514,354 0 owned after | no price filed | 2012-02-15 | |
| 2012-02-13 | ORBIMED ADVISORS LLC | ORBIMED CAPITAL LLC | OrbiMed Capital GP I LLC | ISALY SAMUEL D 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series B Preferred Stock Derivative · Indirect · See Footnotes | C Conversion of derivative security | −1,574,345 0 owned after | no price filed | 2012-02-15 | |
| 2012-02-13 | ORBIMED ADVISORS LLC | ORBIMED CAPITAL LLC | OrbiMed Capital GP I LLC | ISALY SAMUEL D 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series C Preferred Stock Derivative · Indirect · See Footnotes | C Conversion of derivative security | −242,674 0 owned after | no price filed | 2012-02-15 | |
| 2012-02-13 | PENHOET EDWARD Director | 4 | Series B Preferred Stock Derivative · Indirect · By Alta BioPharma Partners III GmbH & Co. Beteiligungs KG | C Conversion of derivative security | −201,097 0 owned after | no price filed | 2012-02-15 | |
| 2012-02-13 | PENHOET EDWARD Director | 4 | Series C Preferred Stock Derivative · Indirect · By Alta BioPharma Partners III GmbH & Co. Beteligungs KG | C Conversion of derivative security | −28,723 0 owned after | no price filed | 2012-02-15 | |
| 2012-02-13 | PENHOET EDWARD Director | 4 | Series B Preferred Stock Derivative · Indirect · By Alta BioPharma Partners III, L.P. | C Conversion of derivative security | −2,994,341 0 owned after | no price filed | 2012-02-15 | |
| 2012-02-13 | PENHOET EDWARD Director | 4 | Series C Preferred Stock Derivative · Indirect · By Alta BioPharma Partners III, L.P. | C Conversion of derivative security | −427,683 0 owned after | no price filed | 2012-02-15 | |
| 2012-02-13 | PENHOET EDWARD Director | 4 | Series B Preferred Stock Derivative · Indirect · By Alta Embarcadero BioPharma Partners III, LLC | C Conversion of derivative security | −73,793 0 owned after | no price filed | 2012-02-15 | |
| 2012-02-13 | PENHOET EDWARD Director | 4 | Series C Preferred Stock Derivative · Indirect · By Alta Embarcadero BioPharma Partners III, LLC | C Conversion of derivative security | −10,540 0 owned after | no price filed | 2012-02-15 | |
| 2012-02-13 | GLAXOSMITHKLINE PLC 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · By Corporation | C Conversion of derivative security | −6,493,506 0 owned after | $0.00 | 2012-02-15 | |
| 2012-02-13 | GLAXOSMITHKLINE PLC 10% Owner | 4 | Series E Preferred Stock Derivative · Indirect · By Corporation | C Conversion of derivative security | −6,793,478 0 owned after | $0.00 | 2012-02-15 | |
| 2012-02-13 | TECHNE CORP /MN/ 10% Owner | 4 | Series A Preferred Stock Derivative · Direct | C Conversion of derivative security | −5,000,000 0 owned after | no price filed | 2012-02-14 | |
| 2012-02-13 | TECHNE CORP /MN/ 10% Owner | 4 | Series B Preferred Stock Derivative · Direct | C Conversion of derivative security | −1,946,836 0 owned after | no price filed | 2012-02-14 | |
| 2012-02-13 | TECHNE CORP /MN/ 10% Owner | 4 | Series C Preferred Stock Derivative · Direct | C Conversion of derivative security | −1,223,148 0 owned after | no price filed | 2012-02-14 | |
| 2012-02-13 | TECHNE CORP /MN/ 10% Owner | 4 | Series D Preferred Stock Derivative · Direct | C Conversion of derivative security | −1,257,149 0 owned after | no price filed | 2012-02-14 | |
| 2012-02-13 | LUCAS ROGER C Director | 4 | Series B Preferred Stock Derivative · Direct | C Conversion of derivative security | −100,000 0 owned after | no price filed | 2012-02-14 | |
| 2012-02-09 holding as of filing | GLAXOSMITHKLINE PLC 10% Owner | 3 | Series D Preferred Stock Derivative · Indirect · By Corporation | Holding | no price filed | 2012-02-09 | ||
| 2012-02-09 holding as of filing | GLAXOSMITHKLINE PLC 10% Owner | 3 | Series E Preferred Stock Derivative · Indirect · By Corporation | Holding | no price filed | 2012-02-09 | ||
| 2012-02-08 holding as of filing | LUCAS ROGER C Director | 3 | Series B Preferred Stock Derivative · Direct | Holding | no price filed | 2012-02-08 | ||
| 2012-02-08 holding as of filing | ORBIMED CAPITAL LLC | ISALY SAMUEL D | ORBIMED ADVISORS LLC | OrbiMed Capital GP I LLC 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series B Preferred Stock Derivative · Indirect · See Footnotes | Holding | no price filed | 2012-02-08 | ||
| 2012-02-08 holding as of filing | ORBIMED CAPITAL LLC | ISALY SAMUEL D | ORBIMED ADVISORS LLC | OrbiMed Capital GP I LLC 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series C Preferred Stock Derivative · Indirect · See Footnotes | Holding | no price filed | 2012-02-08 | ||
| 2012-02-08 holding as of filing | ORBIMED CAPITAL LLC | ISALY SAMUEL D | ORBIMED ADVISORS LLC | OrbiMed Capital GP I LLC 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series B Preferred Stock Derivative · Indirect · See Footnotes | Holding | no price filed | 2012-02-08 | ||
| 2012-02-08 holding as of filing | ORBIMED CAPITAL LLC | ISALY SAMUEL D | ORBIMED ADVISORS LLC | OrbiMed Capital GP I LLC 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series C Preferred Stock Derivative · Indirect · See Footnotes | Holding | no price filed | 2012-02-08 | ||
| 2012-02-08 holding as of filing | ORBIMED CAPITAL LLC | ISALY SAMUEL D | ORBIMED ADVISORS LLC | OrbiMed Capital GP I LLC 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series B Preferred Stock Derivative · Indirect · See Footnotes | Holding | no price filed | 2012-02-08 | ||
| 2012-02-08 holding as of filing | ORBIMED CAPITAL LLC | ISALY SAMUEL D | ORBIMED ADVISORS LLC | OrbiMed Capital GP I LLC 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series C Preferred Stock Derivative · Indirect · See Footnotes | Holding | no price filed | 2012-02-08 | ||
| 2012-02-08 holding as of filing | TECHNE CORP /MN/ 10% Owner | 3 | Series A Preferred Stock Derivative · Direct | Holding | no price filed | 2012-02-08 | ||
| 2012-02-08 holding as of filing | TECHNE CORP /MN/ 10% Owner | 3 | Series B Preferred Stock Derivative · Direct | Holding | no price filed | 2012-02-08 | ||
| 2012-02-08 holding as of filing | TECHNE CORP /MN/ 10% Owner | 3 | Series C Preferred Stock Derivative · Direct | Holding | no price filed | 2012-02-08 | ||
| 2012-02-08 holding as of filing | TECHNE CORP /MN/ 10% Owner | 3 | Series D Preferred Stock Derivative · Direct | Holding | no price filed | 2012-02-08 | ||
| 2012-02-08 holding as of filing | PENHOET EDWARD Director | 3 | Series B Preferred Stock Derivative · Indirect · By Alta BioPharma Partners III GmbH & Co. Beteligungs KG | Holding | no price filed | 2012-02-08 | ||
| 2012-02-08 holding as of filing | PENHOET EDWARD Director | 3 | Series C Preferred Stock Derivative · Indirect · By Alta BioPharma Partners III GmbH & Co. Beteligungs KG | Holding | no price filed | 2012-02-08 | ||
| 2012-02-08 holding as of filing | PENHOET EDWARD Director | 3 | Series B Preferred Stock Derivative · Indirect · By Alta BioPharma Partners III, L.P. | Holding | no price filed | 2012-02-08 | ||
| 2012-02-08 holding as of filing | PENHOET EDWARD Director | 3 | Series C Preferred Stock Derivative · Indirect · By Alta BioPharma Partners III, L.P. | Holding | no price filed | 2012-02-08 | ||
| 2012-02-08 holding as of filing | PENHOET EDWARD Director | 3 | Series B Preferred Stock Derivative · Indirect · By Alta Embarcadero BioPharma Partners III, LLC | Holding | no price filed | 2012-02-08 | ||
| 2012-02-08 holding as of filing | PENHOET EDWARD Director | 3 | Series C Preferred Stock Derivative · Indirect · By Alta Embarcadero BioPharma Partners III, LLC | Holding | no price filed | 2012-02-08 |